首页> 中文期刊> 《世界核心医学期刊文摘:神经病学分册》 >重组组织纤溶酶原激活剂治疗急性缺血性卒中的性别差异:一个临床随机试验的汇总分析

重组组织纤溶酶原激活剂治疗急性缺血性卒中的性别差异:一个临床随机试验的汇总分析

         

摘要

cqvip:Background and Purpose - Women experience worse outcomes after stroke compared with men. Prior work has suggested sex- based differences in coagulation and fibrinolysis markers in subjects with acute stroke. We explored whether sex might modify the effect of recombinant tissue plasminogen activator (rtPA) on outcomes in patients with acute ischemic stroke. Methods - Using a combined database including subjects from the National Institute of Neurological Disorders and Stroke (NINDS), Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke (ATLANTIS) A and B, and the Second European Cooperative Acute Stroke Study (ECASS II) trials, we examined 90- day outcomes in patients randomized to rtPA versus placebo by sex. We used logistic regression to control for potential confounders. Results - Among 988 women treated between 0 and 6 hours from symptom onset, patients receiving rtPA were significantly more likely than those receiving placebo to have a modified Rankin Score ≤ 1 (40.5% versus 30.3% , P<0.0008). Among 1190 men, the trend toward benefit in the overall group did not reach statistical significance (38.5% versus 36.7% , P=0.52). An unadjusted analysis showed that women were significantly more likely to benefit from rtPA compared with men (P=0.04). Controlling for age, baseline National Institutes of Health Stroke Scale, diabetes, symptom onset to treatment time, prior stroke, systolic blood pressure, extent of hypoattenuation on baseline computed tomography scan and several significant interaction terms (including onset to treatment time- by- treatment and systolic blood pressure- by treatment) did not substantially change the strength of the interaction between gender and rtPA treatment (P=0.04). Conclusions - In this pooled analysis of rtPA in acute ischemic stroke, women benefited more than men, and the usual gender difference in outcome favoring men was not observed in the thrombolytic therapy group. For patients presenting at later time intervals, when the risks and benefits of rtPA are more finely balanced, sex may be an important variable to consider for patient selection.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号